{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:07:33Z","timestamp":1784693253329,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2023JJ30847"],"award-info":[{"award-number":["2023JJ30847"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Hunan Provincial Key Laboratory of the Traditional Chinese Medicine Agricultural Biogenomic"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s10637-025-01522-x","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T06:55:30Z","timestamp":1741589730000},"page":"293-300","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical features, treatment, and prognosis of nivolumab induced immune encephalitis"],"prefix":"10.1007","volume":"43","author":[{"given":"Zhaoquan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronghui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"issue":"6","key":"1522_CR1","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1056\/NEJMoa2215530","volume":"389","author":"M Provencio","year":"2023","unstructured":"Provencio M, Nadal E, Gonz\u00e1lez-Larriba JL, Mart\u00ednez-Mart\u00ed A, Bernab\u00e9 R, Bosch-Barrera J et al (2023) Perioperative nivolumab and chemotherapy in stage III Non-Small-Cell lung Cancer. N Engl J Med 389(6):504\u2013513. https:\/\/doi.org\/10.1056\/NEJMoa2215530","journal-title":"N Engl J Med"},{"issue":"2","key":"1522_CR2","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1200\/JCO.21.02961","volume":"41","author":"PF Ferrucci","year":"2023","unstructured":"Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V et al (2023) Sequencing of ipilimumab plus nivolumab and Encorafenib plus binimetinib for untreated BRAF-Mutated metastatic melanoma (SECOMBIT): A randomized, Three-Arm, Open-Label phase II trial. J Clin Oncol 41(2):212\u2013221. https:\/\/doi.org\/10.1200\/JCO.21.02961","journal-title":"J Clin Oncol"},{"issue":"2","key":"1522_CR3","doi-asserted-by":"publisher","first-page":"e003844","DOI":"10.1136\/jitc-2021-003844","volume":"10","author":"SS Tykodi","year":"2022","unstructured":"Tykodi SS, Gordan LN, Alter RS, Arrowsmith E, Harrison MR, Percent I et al (2022) Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b\/4 checkmate 920 trial. J Immunother Cancer 10(2):e003844. https:\/\/doi.org\/10.1136\/jitc-2021-003844","journal-title":"J Immunother Cancer"},{"issue":"28","key":"1522_CR4","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1200\/JCO.2017.76.6212","volume":"36","author":"YY Janjigian","year":"2018","unstructured":"Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P et al (2018) CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric Cancer. J Clin Oncol 36(28):2836\u20132844. https:\/\/doi.org\/10.1200\/JCO.2017.76.6212","journal-title":"J Clin Oncol"},{"issue":"4","key":"1522_CR5","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1080\/14740338.2020.1757068","volume":"19","author":"AM Czarnecka","year":"2020","unstructured":"Czarnecka AM, Rutkowski P (2020) An update on the safety of nivolumab for the treatment of advanced melanoma. Expert Opin Drug Saf 19(4):409\u2013421. https:\/\/doi.org\/10.1080\/14740338.2020.1757068","journal-title":"Expert Opin Drug Saf"},{"issue":"12","key":"1522_CR6","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C et al (2022) Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 33(12):1217\u20131238. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.001","journal-title":"Ann Oncol"},{"issue":"1","key":"1522_CR7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","volume":"7","author":"DB Johnson","year":"2019","unstructured":"Johnson DB, Manouchehri A, Haugh AM, Quach HT, Balko JM, Lebrun-Vignes B, Mammen A, Moslehi JJ, Salem JE (2019) Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer 7(1):134. https:\/\/doi.org\/10.1186\/s40425-019-0617-x","journal-title":"J Immunother Cancer"},{"key":"1522_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.lungcan.2020.03.006","volume":"143","author":"M Sanchis-Borja","year":"2020","unstructured":"Sanchis-Borja M, Ricordel C, Chiappa AM, Hureaux J, Odier L, Jeannin G et al (2020) Encephalitis related to immunotherapy for lung cancer: analysis of a multicenter cohort. Lung Cancer 143:36\u201339. https:\/\/doi.org\/10.1016\/j.lungcan.2020.03.006","journal-title":"Lung Cancer"},{"key":"1522_CR9","doi-asserted-by":"publisher","first-page":"175628641879986","DOI":"10.1177\/1756286418799864","volume":"11","author":"MC Dalakas","year":"2018","unstructured":"Dalakas MC (2018) Neurological complications of immune checkpoint inhibitors: what happens when you \u2018take the brakes off\u2019 the immune system. Ther Adv Neurol Disord 11:1756286418799864. https:\/\/doi.org\/10.1177\/1756286418799864","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"1522_CR10","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s10637-023-01347-6","volume":"41","author":"C Wang","year":"2023","unstructured":"Wang C, Zeng H, Fang W, Song L (2023) Clinical characteristics, treatment and outcome of nivolumab-induced myasthenia Gravis. Invest New Drugs 41(2):333\u2013339. https:\/\/doi.org\/10.1007\/s10637-023-01347-6","journal-title":"Invest New Drugs"},{"issue":"10","key":"1522_CR11","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","volume":"74","author":"JC Kao","year":"2017","unstructured":"Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP, Liewluck T, Hammack JE, Sandroni P, Finnes H, Mauermann ML (2017) Neurological complications associated with Anti-Programmed death 1 (PD-1) antibodies. JAMA Neurol 74(10):1216\u20131222. https:\/\/doi.org\/10.1001\/jamaneurol.2017.1912","journal-title":"JAMA Neurol"},{"issue":"1","key":"1522_CR12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s40425-019-0645-6","volume":"7","author":"MA Couey","year":"2019","unstructured":"Couey MA, Bell RB, Patel AA, Romba MC, Crittenden MR, Curti BD et al (2019) Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. J Immunother Cancer 7(1):165. https:\/\/doi.org\/10.1186\/s40425-019-0645-6","journal-title":"J Immunother Cancer"},{"issue":"19","key":"1522_CR13","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","volume":"28","author":"JR Brahmer","year":"2010","unstructured":"Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH et al (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and Immunologic correlates. J Clin Oncol 28(19):3167\u20133175. https:\/\/doi.org\/10.1200\/JCO.2009.26.7609","journal-title":"J Clin Oncol"},{"issue":"2","key":"1522_CR14","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1212\/WNL.0000000000012122","volume":"97","author":"V Nersesjan","year":"2021","unstructured":"Nersesjan V, McWilliam O, Krarup LH, Kondziella D (2021) Autoimmune encephalitis related to Cancer treatment with immune checkpoint inhibitors: A systematic review. Neurology 97(2):e191\u2013e202. https:\/\/doi.org\/10.1212\/WNL.0000000000012122","journal-title":"Neurology"},{"key":"1522_CR15","doi-asserted-by":"publisher","first-page":"175628642098532","DOI":"10.1177\/1756286420985323","volume":"14","author":"MF Devine","year":"2021","unstructured":"Devine MF, Kothapalli N, Elkhooly M, Dubey D (2021) Paraneoplastic neurological syndromes: clinical presentations and management. Ther Adv Neurol Disord 14:1756286420985323. https:\/\/doi.org\/10.1177\/1756286420985323","journal-title":"Ther Adv Neurol Disord"},{"issue":"12","key":"1522_CR16","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/nrneurol.2017.144","volume":"13","author":"LM Yshii","year":"2017","unstructured":"Yshii LM, Hohlfeld R, Liblau RS (2017) Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives. Nat Rev Neurol 13(12):755\u2013763. https:\/\/doi.org\/10.1038\/nrneurol.2017.144","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"1522_CR17","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41409-018-0363-6","volume":"54","author":"A De la Hoz","year":"2019","unstructured":"De la Hoz A, Foolad F, Gallegos C, Kornblau S, Kontoyiannis DP (2019) Nivolumab-induced encephalitis post allogeneic stem cell transplant in a patient with Hodgkin\u2019s disease. Bone Marrow Transpl 54(5):749\u2013751. https:\/\/doi.org\/10.1038\/s41409-018-0363-6","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"1522_CR18","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1634\/theoncologist.2016-0487","volume":"22","author":"J Larkin","year":"2017","unstructured":"Larkin J, Chmielowski B, Lao CD, Hodi FS, Sharfman W, Weber J et al (2017) Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist 22(6):709\u2013718. https:\/\/doi.org\/10.1634\/theoncologist.2016-0487","journal-title":"Oncologist"},{"key":"1522_CR19","doi-asserted-by":"publisher","unstructured":"Khan AR, Hams E, Floudas A, Sparwasser T, Weaver CT, Fallon PG (2015) PD-L1hi B cells are critical regulators of humoral immunity. Nat Commun 6:5997. https:\/\/doi.org\/10.1038\/ncomms6997. PMID: 25609381","DOI":"10.1038\/ncomms6997"},{"issue":"36","key":"1522_CR20","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M et al (2021) Management of immune-Related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39(36):4073\u20134126. https:\/\/doi.org\/10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"issue":"17","key":"1522_CR21","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM et al (2018) Management of immune-Related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol 36(17):1714\u20131768. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"issue":"6","key":"1522_CR22","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/ajco.13375","volume":"16","author":"S Fan","year":"2020","unstructured":"Fan S, Ren H, Zhao L, Yin J, Feng G, Wang J, Guan H (2020) Neurological immune-related adverse events associated with immune checkpoint inhibitors: A review of the literature. Asia Pac J Clin Oncol 16(6):291\u2013298. https:\/\/doi.org\/10.1111\/ajco.13375","journal-title":"Asia Pac J Clin Oncol"},{"issue":"1","key":"1522_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-019-03273-1","volume":"145","author":"K Sato","year":"2019","unstructured":"Sato K, Mano T, Iwata A, Toda T (2019) Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese adverse drug event report database. J Neurooncol 145(1):1\u20139. https:\/\/doi.org\/10.1007\/s11060-019-03273-1","journal-title":"J Neurooncol"},{"issue":"3","key":"1522_CR24","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1111\/ene.14692","volume":"28","author":"J Piepgras","year":"2021","unstructured":"Piepgras J, M\u00fcller A, Steffen F, Lotz J, Loquai C, Zipp F et al (2021) Neurofilament light chain levels reflect outcome in a patient with glutamic acid decarboxylase 65 antibody-positive autoimmune encephalitis under immune checkpoint inhibitor therapy. Eur J Neurol 28(3):1086\u20131089. https:\/\/doi.org\/10.1111\/ene.14692","journal-title":"Eur J Neurol"},{"issue":"1","key":"1522_CR25","doi-asserted-by":"publisher","first-page":"e13034","DOI":"10.7759\/cureus.13034","volume":"13","author":"NN Soror","year":"2021","unstructured":"Soror NN, Hemrock L, Shah P, Loges RJ, Tharu B (2021) Brain stem encephalitis in a patient with recurrent small cell lung Cancer treated with immune checkpoint inhibitor: case presentation and review of the literature. Cureus 13(1):e13034. https:\/\/doi.org\/10.7759\/cureus.13034","journal-title":"Cureus"},{"issue":"4","key":"1522_CR26","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.21037\/tlcr-20-1315","volume":"10","author":"A Pous","year":"2021","unstructured":"Pous A, Izquierdo C, Cucurull M, S\u00e1nchez S, Lezcano C, Domenech M et al (2021) Immune-checkpoint inhibitors for lung cancer patients amid the COVID-19 pandemic: a case report of severe meningoencephalitis after switching to an extended-interval higher flat-dose nivolumab regimen. Transl Lung Cancer Res 10(4):1917\u20131923. https:\/\/doi.org\/10.21037\/tlcr-20-1315","journal-title":"Transl Lung Cancer Res"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01522-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01522-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01522-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T13:40:55Z","timestamp":1746193255000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01522-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1522"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01522-x","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,10]]},"assertion":[{"value":"2 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not require an ethical board approval because the study was a retrospective study and did not involve sensitive personal information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}